[ASAP] Pharmacokinetic Bioequivalence between Generic and Originator Orally Inhaled Drug Products: Validity of Administration of Doses above the Approved Single Maximum Dose

AI Summary

This article focuses on examining the pharmacokinetic bioequivalence between generic and originator orally inhaled drug products when doses above the approved single maximum dose are administered. The study likely explores how different doses of generic and originator drugs are metabolized and absorbed in the body, assessing their bioequivalence. This research is important for determining the efficacy and safety of generic versions of orally inhaled drugs, especially when doses exceed the approved maximum, potentially impacting clinical practice and regulatory decisions.